These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 8915301)

  • 1. Elimination of ioversol by hemodialysis.
    Ueda J; Furukawa T; Takahashi S; Sakaguchi K
    Acta Radiol; 1996 Sep; 37(5):826-9. PubMed ID: 8915301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elimination of iomeprol by hemodialysis.
    Ueda J; Furukawa T; Higashino K; Takahashi S; Araki Y; Sakaguchi K
    Eur J Radiol; 1996 Nov; 23(3):197-200. PubMed ID: 9003924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elimination of iohexol, a low osmolar nonionic contrast medium, by hemodialysis in patients with chronic renal failure.
    Waaler A; Svaland M; Fauchald P; Jakobsen JA; Kolmannskog F; Berg KJ
    Nephron; 1990; 56(1):81-5. PubMed ID: 2234253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elimination of low-osmolality contrast media by hemodialysis.
    Furukawa T; Ueda J; Takahashi S; Sakaguchi K
    Acta Radiol; 1996 Nov; 37(6):966-71. PubMed ID: 8995475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing residual renal function and efficiency of hemodialysis--an application for urographic contrast media.
    Sterner G; Frennby B; Månsson S; Ohlsson A; Prütz KG; Almén T
    Nephron; 2000 Aug; 85(4):324-33. PubMed ID: 10940743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodialysis for removal of iodinated contrast media.
    Rault RM
    Int J Artif Organs; 2001 Jun; 24(6):331-4. PubMed ID: 11482498
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetics of iopentol in patients with chronic renal failure.
    Svaland MG; Kolmannskog F; Lillevold PE; Nordal KP; Ressem L; Berg KJ
    Acta Radiol; 1992 Sep; 33(5):482-4. PubMed ID: 1389660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using highly concentrated gadobutrol as an MR contrast agent in patients also requiring hemodialysis: safety and dialysability.
    Tombach B; Bremer C; Reimer P; Matzkies F; Schaefer RM; Ebert W; Geens V; Eisele J; Heindel W
    AJR Am J Roentgenol; 2002 Jan; 178(1):105-9. PubMed ID: 11756100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of haemodialysis after contrast medium administration in patients with renal insufficiency.
    Lehnert T; Keller E; Gondolf K; Schäffner T; Pavenstädt H; Schollmeyer P
    Nephrol Dial Transplant; 1998 Feb; 13(2):358-62. PubMed ID: 9509446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of iodinated contrast media in patients with end-stage renal disease.
    Khan SF; Kalantari K
    Semin Dial; 2014; 27(6):607-10. PubMed ID: 24995430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elimination of the nonionic contrast medium iopromide in end-stage renal failure by hemodialysis.
    Kierdorf H; Kindler J; Winterscheid R; Hollmann HJ; Vorwerk D; Speck U
    Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd; 1989; 128():119-23. PubMed ID: 2568779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elimination of non-ionic contrast medium by hemodialysis in patients with impaired renal function.
    Horiuchi K; Yoshida K; Tsuboi N; Akimoto M; Tajima H; Kumazaki T
    Nihon Ika Daigaku Zasshi; 1999 Oct; 66(5):305-7. PubMed ID: 10547995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced iopromide elimination in hemodialysis with cuprophan membranes.
    Matzkies FK; Reinecke H; Tombach B; Koeneke J; Hohage H; Kisters K; Schaefer RM
    Acta Radiol; 2000 Nov; 41(6):671-3. PubMed ID: 11092496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biodistribution and excretion of 125I ioversol in conscious dogs.
    Coveney JR; Robbins MS
    Invest Radiol; 1989 Jun; 24 Suppl 1():S23-7. PubMed ID: 2592170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the low-osmolality contrast medium ioversol (Optiray) on renal function in a geriatric population.
    Louvel JP; Primard E; Henry J; Houlette C; Weinstein A; Janvresse A
    Acta Radiol; 1996 Nov; 37(6):950-3. PubMed ID: 8995472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of contrast material for spiral CT of the abdomen: comparison of hepatic enhancement and vascular attenuation for three different contrast media at two different delay times.
    Herts BR; Paushter DM; Einstein DM; Zepp R; Friedman RA; Obuchowski N
    AJR Am J Roentgenol; 1995 Feb; 164(2):327-31. PubMed ID: 7839963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A very rare case of encephalopathy in a patient with end-stage renal disease: contrast agent, ioversol.
    Ozelsancak R; Erken E; Yildiz I; Giray S; Yildirim T; Micozkadioglu H
    Ren Fail; 2010; 32(9):1128-30. PubMed ID: 20863223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical tolerability of ioversol 300 in brain computed tomography].
    Gillard C; Tatu L; Menegazzo D; Bonneville JF
    Ann Radiol (Paris); 1992; 35(4 Pt 2):284-7. PubMed ID: 1296493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and pharmacokinetics of ioversol in healthy volunteers.
    Wilkins RA; Whittington JR; Brigden GS; Lahiri A; Heber ME; Hughes LO
    Invest Radiol; 1989 Oct; 24(10):781-8. PubMed ID: 2793391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An observational study to evaluate the efficiency and safety of ioversol pre-filled syringes compared with ioversol bottles in contrast-enhanced examinations.
    Vogl TJ; Wessling J; Buerke B
    Acta Radiol; 2012 Oct; 53(8):914-20. PubMed ID: 22983259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.